These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24457041)

  • 1. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia.
    Melani A; Corti F; Cellai L; Vannucchi MG; Pedata F
    Brain Res; 2014 Mar; 1551():59-72. PubMed ID: 24457041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
    Melani A; Cipriani S; Vannucchi MG; Nosi D; Donati C; Bruni P; Giovannini MG; Pedata F
    Brain; 2009 Jun; 132(Pt 6):1480-95. PubMed ID: 19359287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia.
    Melani A; Gianfriddo M; Vannucchi MG; Cipriani S; Baraldi PG; Giovannini MG; Pedata F
    Brain Res; 2006 Feb; 1073-1074():470-80. PubMed ID: 16443200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.
    Culman J; Nguyen-Ngoc M; Glatz T; Gohlke P; Herdegen T; Zhao Y
    Exp Neurol; 2012 Dec; 238(2):243-53. PubMed ID: 22995601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia.
    Melani A; Dettori I; Corti F; Cellai L; Pedata F
    Neurol Sci; 2015 Aug; 36(8):1441-8. PubMed ID: 25805704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.
    Schindler CW; Karcz-Kubicha M; Thorndike EB; Müller CE; Tella SR; Ferré S; Goldberg SR
    Br J Pharmacol; 2005 Mar; 144(5):642-50. PubMed ID: 15678095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat.
    Melani A; Pantoni L; Bordoni F; Gianfriddo M; Bianchi L; Vannucchi MG; Bertorelli R; Monopoli A; Pedata F
    Brain Res; 2003 Jan; 959(2):243-50. PubMed ID: 12493612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.
    Imarisio C; Alchera E; Sutti S; Valente G; Boccafoschi F; Albano E; Carini R
    Clin Sci (Lond); 2012 Sep; 123(5):323-32. PubMed ID: 22439844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.
    Brambilla R; Cottini L; Fumagalli M; Ceruti S; Abbracchio MP
    Glia; 2003 Aug; 43(2):190-4. PubMed ID: 12838511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects.
    Paterniti I; Melani A; Cipriani S; Corti F; Mello T; Mazzon E; Esposito E; Bramanti P; Cuzzocrea S; Pedata F
    J Neuroinflammation; 2011 Apr; 8():31. PubMed ID: 21486435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-ischemic treatment of pentoxifylline reduces cortical not striatal infarct volume in transient model of focal cerebral ischemia in rat.
    Vakili A; Zahedi khorasani M
    Brain Res; 2007 May; 1144():186-91. PubMed ID: 17320054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained reversal of central neuropathic pain induced by a single intrathecal injection of adenosine A
    Kwilasz AJ; Ellis A; Wieseler J; Loram L; Favret J; McFadden A; Springer K; Falci S; Rieger J; Maier SF; Watkins LR
    Brain Behav Immun; 2018 Mar; 69():470-479. PubMed ID: 29366930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
    Antonelli T; Fuxe K; Agnati L; Mazzoni E; Tanganelli S; Tomasini MC; Ferraro L
    J Neurol Sci; 2006 Oct; 248(1-2):16-22. PubMed ID: 16765381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain.
    Trincavelli ML; Melani A; Guidi S; Cuboni S; Cipriani S; Pedata F; Martini C
    J Neurochem; 2008 Jan; 104(2):479-90. PubMed ID: 17953669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK506 protects against various immune responses and secondary degeneration following cerebral ischemia.
    Brecht S; Waetzig V; Hidding U; Hanisch UK; Walther M; Herdegen T; Neiss WF
    Anat Rec (Hoboken); 2009 Dec; 292(12):1993-2001. PubMed ID: 19728359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A
    Ialenti A; Caiazzo E; Morello S; Carnuccio R; Cicala C
    J Pharmacol Exp Ther; 2018 Feb; 364(2):221-228. PubMed ID: 29212832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes.
    Nonaka H; Mori A; Ichimura M; Shindou T; Yanagawa K; Shimada J; Kase H
    Mol Pharmacol; 1994 Nov; 46(5):817-22. PubMed ID: 7969067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of an Adenosine A
    Prasad K; de Vries EFJ; Sijbesma JWA; Garcia-Varela L; Vazquez-Matias DA; Moraga-Amaro R; Willemsen ATM; Dierckx RAJO; van Waarde A
    Mol Pharm; 2022 Aug; 19(8):2992-3001. PubMed ID: 35849844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.